Sphingomyelin-based PEGylation Cu (DDC)2 liposomes prepared via the dual function of Cu2+ for cancer therapy: Facilitating DDC loading and exerting synergistic antitumor effects
Authors:
- 2 May 2022
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 621, 121788
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Liposome: classification, preparation, and applicationsDiscover Nano, 2013
- Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer CellsJournal of Medicinal Chemistry, 2008
- Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome ActivityCancer Research, 2006
- Optimization and Characterization of a Sphingomyelin/Cholesterol Liposome Formulation of Vinorelbine with Promising Antitumor ActivityJournal of Pharmaceutical Sciences, 2005
- Recent advances with liposomes as pharmaceutical carriersNature Reviews Drug Discovery, 2005
- Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicansBiochemical and Biophysical Research Communications, 2004
- Characterization of Cholesterol-Sphingomyelin Domains and Their Dynamics in Bilayer MembranesBiophysical Journal, 2001
- A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolitesActa Psychiatrica Scandinavica, 1992
- Drug entrapment in liposomesFEBS Letters, 1973
- Diffusion of univalent ions across the lamellae of swollen phospholipidsJournal of Molecular Biology, 1965